Wall Street brokerages forecast that Phreesia (NYSE:PHR) will announce earnings of ($0.23) per share for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Phreesia’s earnings, with the lowest EPS estimate coming in at ($0.29) and the highest estimate coming in at ($0.15). The business is expected to issue its next earnings results on Monday, June 8th.
According to Zacks, analysts expect that Phreesia will report full year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.70) to ($0.48). For the next financial year, analysts expect that the company will report earnings of ($0.39) per share, with EPS estimates ranging from ($0.45) to ($0.34). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Phreesia.
Phreesia (NYSE:PHR) last posted its earnings results on Monday, June 8th. The company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07. The business had revenue of $33.40 million during the quarter, compared to the consensus estimate of $25.92 million. Phreesia’s revenue for the quarter was up 18.0% compared to the same quarter last year.
Several analysts have commented on the stock. KeyCorp boosted their target price on shares of Phreesia from $25.00 to $34.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Robert W. Baird upped their price objective on shares of Phreesia from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, April 24th. SVB Leerink began coverage on shares of Phreesia in a report on Monday, April 13th. They set an “outperform” rating and a $24.00 price objective for the company. Guggenheim began coverage on shares of Phreesia in a report on Friday, May 15th. They set a “buy” rating and a $31.00 price objective for the company. Finally, Wells Fargo & Co decreased their price objective on shares of Phreesia from $35.00 to $30.00 and set an “overweight” rating for the company in a report on Friday, April 24th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Phreesia presently has a consensus rating of “Buy” and a consensus price target of $30.08.
In related news, insider Michael J. Davidoff sold 3,851 shares of the company’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $20.06, for a total transaction of $77,251.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Charles Kallenbach sold 2,500 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $27.20, for a total transaction of $68,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 37,219 shares of company stock valued at $884,094. Corporate insiders own 28.20% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Swiss National Bank raised its stake in shares of Phreesia by 1.8% in the 1st quarter. Swiss National Bank now owns 34,800 shares of the company’s stock valued at $732,000 after buying an additional 600 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Phreesia by 8.2% in the 4th quarter. Rhumbline Advisers now owns 9,295 shares of the company’s stock valued at $248,000 after buying an additional 707 shares in the last quarter. Altshuler Shaham Ltd acquired a new position in shares of Phreesia in the 4th quarter valued at $29,000. Bank of Montreal Can acquired a new position in shares of Phreesia in the 4th quarter valued at $33,000. Finally, UBS Group AG raised its stake in shares of Phreesia by 9.9% in the 1st quarter. UBS Group AG now owns 13,921 shares of the company’s stock valued at $293,000 after buying an additional 1,256 shares in the last quarter. Institutional investors own 70.81% of the company’s stock.
PHR stock opened at $32.03 on Tuesday. The company has a quick ratio of 3.72, a current ratio of 3.72 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $1.21 billion and a price-to-earnings ratio of -7.12. Phreesia has a 12 month low of $16.01 and a 12 month high of $34.85. The firm has a 50 day moving average of $27.09 and a two-hundred day moving average of $26.80.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.
Further Reading: What are catch-up contributions?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.